Unusual Toxicity Induced by Radiotherapy (CRYOTOX)
Collection of Biological Samples for Stydy of Unusual Toxicity Induced by Radiotherapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jean Louis MERLIN
- Phone Number: 033383598307
- Email: jl.merlin@nancy.unicancer.fr
Study Contact Backup
- Name: Priscillia TOSTI
- Phone Number: 0033383598657
- Email: p.tosti@nancy.unicancer.fr
Study Locations
-
-
-
Vandœuvre-lès-Nancy, France, 54519
- Institut de Cancérologie de Lorraine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Child or teenager aged 2 to <18
- Man, Woman> 18 years old
Patient with one of these situations:
- Unusual toxicity in progress or after radiotherapy
- Indication of radiotherapy and suspicion of abnormal pathways of response to ionizing radiation - constitutional (genetic disease) or acquired (systemic disease) - which may generate unusual radioinduced toxicity
- Patient information and informed consent signed by the patient. For children and teenager : information to parents and obtaining informed consent
- Affiliation to a social security scheme.
Exclusion Criteria:
- Contraindication for skin and / or tumoral biopsy
- Contraindication for blood sample of 2.5 ml
- Persons deprived of liberty or under supervision
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: skin and/or tumor Biopsy and blood sample
|
skin biopsy will be taken under local anesthesia using a patch of lidocaine and prilocaine.
In practice, during the skin biopsy, the skin must be cleaned with chlorhexidine or alcohol, to the exclusion of any other antiseptic.
The biopsy will preferably be done with a dermatome (or "punch", 12 G).
an additional tumor sample will be taken during programmed diagnostic procedure.
blood sample will be taken for biological collection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
skin fibroblast radiosensitivity
Time Frame: 2 to 3 months after skin biopsy
|
The number of residual double strand break at 24 hours (number of 53BP1 foci) after a dose of 2 Gy will be quantified with indirect immunofluorescence
|
2 to 3 months after skin biopsy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
tumor cells radiosensitivity
Time Frame: 2 to 3 months after tumor biopsy
|
The number of residual double strand break at 24 hours (number of 53BP1 foci) after a dose of 2 Gy will be quantified with indirect immunofluorescence
|
2 to 3 months after tumor biopsy
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 2017 A00266-47
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.